 Several brokerages have updated their recommendations and price targets on shares of Fate Therapeutics NASDAQ: FATE in the last few weeks: 4282020 Fate Therapeutics was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They now have a 34.00 price target on the stock. According to Zacks, Fate ... 